Pharmafile Logo
Pharmafocus logo
Advanced Search
nice

NICE rejects cholesterol drug Praluent in draft guidance

February 8, 2016
Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol

NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …

News
jeremy_hunt_appears_on_thye_bbcs_andrew_marr_show_february_7

UK Health Secretary sets out £4.2 billion ‘digital NHS’ vision

February 8, 2016
Medical Communications, Sales and Marketing Jeremy Hunt, NHS

UK Health Secretary Jeremy Hunt has announced a £4.2 billion investment in the National Health Service (NHS) which will help …

News
shire_image_4

FDA to decide on Shire blockbuster hopeful

February 8, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast

The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …

News
opdivo

UK lung cancer patients get early access to breakthrough BMS drug

February 5, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo

UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …

News
Shkreli hearing

Big pharma answers tough questions at US drug pricing hearing

February 5, 2016
Medical Communications Drug pricing, FDA, Martin Shkreli, Senate, Turing Pharmaceuticals, US, Valeant, congress

Pharmaceutical industry executives came under intense scrutiny at a Congressional hearing in the US as the debate over the spiralling …

News

Parliamentary committee says CDF must make better use of taxpayer money

February 5, 2016
Medical Communications Cancer Drugs Fund, Public Accounts Committee

The Cancer Drugs Fund, set up to improve patients’ access to cancer drugs, has not been managed effectively, a UK …

News
Lundbeck HQ

Lundbeck gets go-ahead for US and EU licence expansions

February 4, 2016
Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine

Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …

News
Xarelto

Investigation questions Xarelto trial data accuracy

February 4, 2016
Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …

News
la76169logo

Human Longevity makes three oncology appointments

February 4, 2016
Research and Development human longevity

Human Longevity, the genomics-based, technology company, has appointed ‘several key people’ for its oncology genomics program.Dr Kenneth Bloom will join …

Appointment
astrazeneca_plaque

AZ warns of patent losses as revenues fall

February 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic

AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …

News
World Cancer Day 2016

Cancer – dealing with the greatest health challenge of our time

February 4, 2016
Manufacturing and Production, Research and Development Cancer, IFPMA, R&D, World Cancer Day, collaboration, partnership

Cancer is one of the greatest health challenges of our time, and a leading cause of death in every corner …

Feature
AZ sign

AstraZeneca’s Tagrisso gets EU lung cancer sign-off

February 4, 2016
Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib

The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …

News
Merck image

Revenues down at MSD

February 4, 2016
Sales and Marketing MSD, financial performance, profits, revenue, sales

MSD (Merck, Sharpe and Dohme) reported a mixed bag of financial figures today, as the company announced full-year 2015 revenues …

News
Spending graph

Emerging markets top global R&D spending league

February 4, 2016
Research and Development GDP, OECD, R&D spending, investment

Data from the Organisation for Economic Co-operation and Development (OECD) shows Korea and Israel are investing much more in research …

News
pills-943764_1920

Revealed: analysts predict seven highest-earning pharma blockbusters

February 4, 2016
Sales and Marketing Gilead, OCA, Thomson Reuters, blockbusters, sales

Seven new drugs currently in development will enter the market this year – and earn sales of more than $1 …

News
rodger_currie

Rodger Currie to lead advocacy at US pharma trade body

February 3, 2016
Medical Communications PhRMA, Pharmaceutical Research and Manufacturers of America

Rodger Currie has joined the Pharmaceutical Research and Manufacturers of America (PhRMA) association as executive vice president for advocacy.He will lead federal, …

Appointment
ICR Sutton

London launches new cancer drug development hub

February 3, 2016
Research and Development

Research charities, hospitals, and London boroughs have combined to launch a new global hub for cancer research and treatment in …

News
Adaptimmune

GSK and Adaptimmune expand R&D collaboration

February 3, 2016
Research and Development Adaptimmune, GSK, T-cell therapy, immunotherapy, liposarcoma, rare cancer, sarcoma

Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run clinical trials of Adaptimmune’s potential …

News
Daiichi Sankyo researchers

Daiichi Sankyo to expand access to clinical trial data

February 3, 2016
Research and Development Daiichi Sankyo, R&D, clinical trials, open access, open data, transparency

Daiichi Sankyo has announced today that it will share clinical trial data to qualified researchers through an online web request …

News
Brandicourt

Sanofi plans R&D jobs cuts in France

February 3, 2016
Manufacturing and Production, Research and Development Sanofi, Teva, cuts, job losses, olivier brandicourt, redundancies

Sanofi chief executive Olivier Brandicourt is reported to be planning hundreds of job cuts across the firm’s base in France, …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026